Drugs / huA33
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00199797 | Apr 2005 → Nov 2006 | colorectal cancer | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00199862 | Feb 2004 → Jul 2025 | colorectal carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | huA33 | “single intravenous or intraarterial infusion of 10mg huA33, labeled with 4mCi-10mCi of 124I in 5-30ml of 5% HSA in normal saline (NS), over 5-10 minutes.” NCT00199862 ↗ |
| Known as | humanized A33 | “Iodine-124 labeled humanized A33 (antibody)” NCT00199862 ↗ |
| Modality | Monoclonal antibody | “In the search for new therapies, monoclonal antibodies have been developed to specifically target human colon cancer cells. huA33 is an antibody that reacts with the A33 antigen” NCT00199797 ↗ |
| Route | Intravenous | “huA33 was administered intravenously over a period of 30 minutes” NCT00199797 ↗ |
| Target | GPA33 | “Cell surface A33 antigen binding agent” CHEMBL2109435 ↗ |